MannKind Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Für MannKind wird ein Gewinn- und Umsatzwachstum von 54.7% bzw. 11.9% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 56% pro Jahr steigen soll.
Wichtige Informationen
54.7%
Wachstumsrate der Gewinne
55.97%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.2% |
| Wachstumsrate der Einnahmen | 11.9% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 02 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • May 11
Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...Analyseartikel • Mar 01
MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next
MannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...Recent updates
Narrativ-Update • Jun 22
MNKD: Pediatric Insulin Approval Will Test Commercial Execution And Reprice Future Upside
The latest narrative update on MannKind reflects a higher analyst price target, moving from $7.17 to $7.59, as analysts highlight Afrezza's pediatric approval while still viewing the company as a "show me" story on commercial execution. Analyst Commentary Recent research on MannKind centers on how Afrezza's pediatric approval could affect the company's long term commercial story, while mixed target moves show differing views on execution risk and valuation.
Narrativ-Update • Jun 05
MNKD: Pediatric Approval And Trial Progress Will Reset Perceived Royalty Risk
Analysts have raised their MannKind price target to $11 from $8. This reflects updated assumptions that include Afrezza's pediatric approval, a lower discount rate, and higher expected profit margins, even as projected revenue growth and future P/E move slightly lower.Seeking Alpha • Jun 03
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
Summary MannKind gains FDA approval for Afrezza pediatric use, expanding its differentiated inhaled insulin therapy to children aged 6+ with type 1 or 2 diabetes. I see Afrezza’s pediatric label extension as a durable growth inflection, targeting a concentrated 360,000-patient U.S. base and 30,000 annual inflow, with an efficient commercial strategy. MNKD estimates a 23–37% pediatric market share, translating to a $300–500 million revenue opportunity, with gradual adoption expected to accelerate meaningfully by 4Q26 and into 2027. Valuation remains discounted at 2.5x forward sales, reflecting execution risk; sustained physician adoption and payer access in 2H26 could drive a market re-rating. Read the full article on Seeking Alpha
Narrativ-Update • May 21
MNKD: 2026 Pediatric Decision Will Shape Royalty Overhang And Rebound Potential
Analysts have updated their view on MannKind with a new fair value estimate of $4.75 per share, reflecting recent shifts in price targets as they balance concerns about Tyvaso DPI royalty risk against ongoing contributions from products like Furoscix and Afrezza. Analyst Commentary Recent research highlights a split in how professionals are valuing MannKind, with much of the debate centered on the durability of Tyvaso DPI royalties and how that uncertainty should be reflected in the share price.Narrativ-Update • May 04
MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty Upside
Narrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.Narrativ-Update • Apr 20
MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty Risk
Analysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.Narrativ-Update • Apr 06
MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish Setup
Narrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.Narrativ-Update • Mar 22
MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty Risk
Analysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.Narrativ-Update • Mar 08
MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty Risk
Analysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.Narrativ-Update • Feb 22
MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case
Analysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.Narrativ-Update • Feb 07
MNKD: Upcoming FDA Decisions In 2026 Will Define Upside Potential
Narrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.Narrativ-Update • Jan 23
MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside Potential
Narrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.Narrativ-Update • Jan 09
MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future Prospects
Narrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.Narrativ-Update • Dec 23
MNKD: Future Commercial Execution Will Offset Late Stage Pipeline Disappointment
Analysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.Narrativ-Update • Dec 09
MNKD: Future Commercial Portfolio Will Offset Pipeline Setback Risk
Analysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.Narrativ-Update • Nov 25
MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties Expansion
Analysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.Narrativ-Update • Nov 11
MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-Rating
MannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.Analyseartikel • Sep 03
MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump
MannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...Narrativ-Update • Aug 27
Pipeline Advancements And International Expansion Will Shape Future Markets
Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.Analyseartikel • May 11
Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...Analyseartikel • Mar 01
MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next
MannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...Seeking Alpha • Dec 17
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Summary MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized. The orphan lung pipeline includes MNKD-101 (Phase 3 for NTM lung disease) and MNKD-201 (Phase 1 for IPF), addressing high unmet needs. Despite high leverage, I believe MNKD's revenue growth prospects support a speculative "Buy" rating for investors seeking exposure to IPF and endocrine biotech niches. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Summary MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. Financially, MannKind has strong liquidity but remains burdened by long-term debt obligations and modest net losses. I maintain a "buy" recommendation based on MannKind's solid revenue from Tyvaso DPI and its potential in expanding respiratory treatments. Read the full article on Seeking AlphaAnalyseartikel • Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Despite an already strong run, MannKind Corporation ( NASDAQ:MNKD ) shares have been powering on, with a gain of 28% in...
Neues Narrativ • Sep 12
Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability
Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.Analyseartikel • Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Key Insights The projected fair value for MannKind is US$11.86 based on 2 Stage Free Cash Flow to Equity MannKind is...Seeking Alpha • May 15
MannKind Outperforms As Tyvaso DPI Captures Market Share
Summary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current assets, the Company's long-term liabilities exceed its assets, posing potential financial risks. Recommend buying MNKD for a barbell strategy portfolio, allocating a small portion to this high-alpha stock. Read the full article on Seeking AlphaAnalyseartikel • Mar 03
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Celebrations may be in order for MannKind Corporation ( NASDAQ:MNKD ) shareholders, with the analysts delivering a...Analyseartikel • Mar 02
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
MannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Feb 15
MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Summary MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a competing formulation poses a slight concern but is unlikely to significantly impact MannKind's market share. MannKind's Q3 earnings showed a strong year-over-year surge, but concerns over equity dilution and a debt-heavy balance sheet remain. MannKind's strategic moves, financial strengthening via the Sagard deal, and a manageable competitive landscape advocate for a "Buy" rating. Read the full article on Seeking AlphaAnalyseartikel • Jan 03
MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
MannKind Corporation's ( NASDAQ:MNKD ) price-to-sales (or "P/S") ratio of 6x might make it look like a strong buy right...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 536 | 71 | 39 | 90 | 8 |
| 12/31/2027 | 521 | 57 | 87 | 84 | 8 |
| 12/31/2026 | 462 | -1 | 42 | 32 | 8 |
| 3/31/2026 | 361 | -24 | 13 | 19 | N/A |
| 12/31/2025 | 349 | 6 | 14 | 18 | N/A |
| 9/30/2025 | 314 | 29 | 43 | 49 | N/A |
| 6/30/2025 | 302 | 33 | 29 | 35 | N/A |
| 3/31/2025 | 298 | 30 | 22 | 29 | N/A |
| 12/31/2024 | 286 | 28 | 33 | 43 | N/A |
| 9/30/2024 | 267 | 22 | 29 | 42 | N/A |
| 6/30/2024 | 248 | 12 | 18 | 41 | N/A |
| 3/31/2024 | 225 | 8 | 3 | 40 | N/A |
| 12/31/2023 | 199 | -12 | -8 | 34 | N/A |
| 9/30/2023 | 177 | -31 | -32 | 10 | N/A |
| 6/30/2023 | 158 | -47 | -57 | -27 | N/A |
| 3/31/2023 | 128 | -71 | -72 | -61 | N/A |
| 12/31/2022 | 100 | -87 | -88 | -81 | N/A |
| 9/30/2022 | 76 | -98 | -98 | -91 | N/A |
| 6/30/2022 | 66 | -88 | -89 | -78 | N/A |
| 3/31/2022 | 70 | -94 | -83 | -67 | N/A |
| 12/31/2021 | 75 | -81 | -73 | -62 | N/A |
| 9/30/2021 | 81 | -79 | -60 | -49 | N/A |
| 6/30/2021 | 75 | -86 | -54 | -47 | N/A |
| 3/31/2021 | 66 | -61 | -35 | -30 | N/A |
| 12/31/2020 | 65 | -57 | -33 | -28 | N/A |
| 9/30/2020 | 63 | -45 | -34 | -33 | N/A |
| 6/30/2020 | 62 | -44 | -73 | -72 | N/A |
| 3/31/2020 | 62 | -46 | -91 | -88 | N/A |
| 12/31/2019 | 63 | -52 | N/A | -88 | N/A |
| 9/30/2019 | 63 | -47 | N/A | -58 | N/A |
| 6/30/2019 | 53 | -61 | N/A | -20 | N/A |
| 3/31/2019 | 42 | -71 | N/A | -28 | N/A |
| 12/31/2018 | 28 | -87 | N/A | -38 | N/A |
| 9/30/2018 | 16 | -110 | N/A | -93 | N/A |
| 6/30/2018 | 13 | -119 | N/A | -102 | N/A |
| 3/31/2018 | 12 | -131 | N/A | -95 | N/A |
| 12/31/2017 | 11 | -117 | N/A | -65 | N/A |
| 9/30/2017 | 20 | -31 | N/A | -48 | N/A |
| 6/30/2017 | 180 | 129 | N/A | -47 | N/A |
| 3/31/2017 | 178 | 134 | N/A | -39 | N/A |
| 12/31/2016 | 175 | 126 | N/A | -78 | N/A |
| 9/30/2016 | 162 | -205 | N/A | -88 | N/A |
| 6/30/2016 | N/A | -364 | N/A | -85 | N/A |
| 3/31/2016 | N/A | -363 | N/A | -91 | N/A |
| 12/31/2015 | N/A | -368 | N/A | -57 | N/A |
| 9/30/2015 | N/A | -128 | N/A | -70 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: MNKD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.5%).
Ertrag vs. Markt: MNKD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: MNKD wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: MNKDDie Einnahmen des Unternehmens (11.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (12.7% pro Jahr).
Hohe Wachstumseinnahmen: MNKDDie Einnahmen des Unternehmens (11.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MNKD in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/29 09:18 |
| Aktienkurs zum Tagesende | 2026/06/29 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
MannKind Corporation wird von 27 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |